How to transfer my Strattera prescription to California

If you’ve been wondering whether you can get ADHD non-stimulant medication like Strattera prescribed through a telehealth visit, you’re not alone. With the rise of online healthcare, many people are seeking convenient, accessible ways to manage their ADHD symptoms without the traditional barriers of in-person appointments.

The short answer? Yes, you can get non-stimulant ADHD medications prescribed via telehealth in most cases. But the longer answer involves understanding federal regulations, state-specific rules, and what to expect from a legitimate telehealth provider.

Let’s break down everything you need to know about getting ADHD non-stimulant medications through telehealth in 2025.

Understanding Non-Stimulant ADHD Medications

Before diving into telehealth regulations, it’s important to understand what non-stimulant ADHD medications are and how they differ from stimulants like Adderall or Ritalin.

Strattera (atomoxetine) is the most commonly prescribed non-stimulant ADHD medication. Unlike stimulant medications, Strattera is not a controlled substance according to the DEA. This distinction is crucial because it means Strattera isn’t subject to the same strict prescribing regulations that apply to stimulants.

Non-stimulant medications work differently in your brain than stimulants do. While stimulants increase dopamine and norepinephrine levels quickly (often working within hours), Strattera gradually increases norepinephrine over time. This means it typically takes 4–6 weeks to see the full therapeutic benefits.

Why Choose a Non-Stimulant?

Non-stimulant medications might be the right choice if you:

• Have a history of substance abuse or concerns about medication dependency
• Experience problematic side effects from stimulants (like anxiety, sleep issues, or appetite suppression)
• Have certain medical conditions that make stimulants risky (such as uncontrolled high blood pressure or heart problems)
• Prefer a medication that provides all-day coverage without wearing off
• Want to avoid the monthly prescription refill requirements that come with controlled substances

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: What the DEA Says About Telehealth Prescribing

The Drug Enforcement Administration (DEA) has been at the center of telehealth prescribing discussions, especially since the COVID-19 pandemic changed how healthcare is delivered.

Here’s the critical point: Non-stimulant ADHD medications like Strattera are not subject to DEA restrictions on telehealth prescribing. Since Strattera isn’t a controlled substance, the Ryan Haight Act’s requirement for an in-person medical evaluation before prescribing controlled substances online simply doesn’t apply.

Current Status of DEA Telehealth Rules

As of December 2025, the DEA has extended pandemic-era telehealth flexibilities for controlled substances (Schedules II–V) through December 31, 2025. This mainly affects stimulant ADHD medications like Adderall, Vyvanse, and Ritalin.

What does this mean for you? If you’re seeking non-stimulant treatment, you’re in a much simpler regulatory position. Your licensed telehealth provider can evaluate you via video, confirm an ADHD diagnosis, and prescribe Strattera without any federal requirement for a prior in-person visit.

However, it’s worth noting that the telehealth landscape for stimulant medications may change in 2026 if the DEA doesn’t extend these flexibilities or implement new permanent regulations. Many expect either another extension or a new framework that might require periodic in-person visits for controlled substance prescriptions.

State-by-State Variations: Know Your Local Rules

While federal law sets the baseline, individual states have their own telehealth regulations. The good news is that no state outright bans telehealth treatment for ADHD, and most have embraced expanded telehealth access.

Here’s what you need to know about key states:

California

California is telehealth-friendly with no mandatory in-person exam requirement for non-controlled medications. The state allows nurse practitioners to practice independently (after meeting experience requirements), broadening access to ADHD care. Proposed legislation (AB 1503) aims to further modernize tele-prescribing definitions, though it’s still pending as of late 2025.

New York

New York implemented stricter rules in 2025, requiring an initial in-person evaluation before prescribing any controlled substance via telehealth. However, this doesn’t affect Strattera or other non-controlled medications. If you’re seeking non-stimulant treatment in New York, you can start via telehealth without an in-person visit. New York also allows nurse practitioners to practice independently after completing 3,600 supervised hours.

Florida

Florida generally permits telehealth for ADHD treatment, including for psychiatric conditions. The state requires checking the Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription, but this doesn’t apply to Strattera. Florida does have restrictions on nurse practitioners and physician assistants prescribing Schedule II medications independently, but physicians can prescribe both stimulants and non-stimulants via telehealth.

Texas

Texas is notably telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. However, nurse practitioners face limitations—they can only prescribe Schedule II stimulants in hospital or hospice settings. Physicians have full prescribing authority via telehealth for ADHD medications, including both stimulants (under current federal waivers) and non-stimulants like Strattera.

Alabama

Alabama has some of the strictest telehealth rules in the country. The state requires an in-person visit within 12 months for ongoing telehealth treatment, with some exceptions for mental health services. Alabama also requires that a nurse or other healthcare professional be physically present with the patient during initial controlled substance prescriptions via telehealth. These rules primarily affect controlled medications, not Strattera.

New Hampshire

New Hampshire recently modernized its telehealth laws in August 2025, removing previous in-person requirements and now only requiring at least an annual follow-up evaluation for controlled substance prescriptions (which can be done via telehealth). This makes New Hampshire one of the most progressive states for telehealth ADHD treatment.

Who Can Prescribe ADHD Medications Via Telehealth?

Understanding which healthcare providers can prescribe ADHD medications is important when choosing a telehealth service.

Physicians (MD/DO)

Licensed physicians in all states can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they follow DEA and state regulations. When you work with a telehealth platform like Klarity Health, you’re matched with board-certified physicians licensed in your state who have the appropriate DEA registration.

Nurse Practitioners and Physician Assistants

The prescribing authority of nurse practitioners (NPs) and physician assistants (PAs) varies significantly by state:

Independent Practice States: Over 20 states now allow NPs to prescribe controlled substances independently after completing certain training and experience requirements. These include New York, Illinois, California, and New Hampshire.

Collaborative Practice States: Other states require NPs and PAs to work under a collaborative agreement with a physician. In these states, the supervising physician’s delegation determines what the NP or PA can prescribe.

Restricted States: A few states, like Georgia, don’t allow NPs to prescribe Schedule II stimulants at all, even under physician supervision. In Texas, NPs can only prescribe Schedule II medications in hospital or hospice settings.

The good news: In all states, NPs and PAs with appropriate supervision or independent authority can prescribe non-stimulant medications like Strattera.

What to Expect from a Legitimate Telehealth ADHD Evaluation

If you’re considering telehealth for ADHD treatment, it’s important to understand that a legitimate evaluation isn’t a quick rubber-stamp process. Reputable providers follow the same diagnostic standards as in-person visits.

The Evaluation Process

Comprehensive Intake: Expect to complete detailed questionnaires about your symptoms, medical history, and how ADHD affects your daily life. You’ll answer questions about symptoms in multiple settings—work, school, home, relationships—and when symptoms first appeared.

Video Consultation: You’ll have a live video appointment with a licensed provider. This isn’t a text chat or phone call—federal and state regulations typically require audio-visual communication for prescribing medications. During this visit, the provider will:

• Review your symptom history in detail
• Ask about your childhood and whether symptoms were present before age 12 (a key diagnostic criterion)
• Discuss your mental health history and any other conditions
• Review previous ADHD diagnoses or treatments
• Screen for conditions that might contraindicate certain medications
• Evaluate your medical history for safety concerns

Diagnostic Criteria: The provider will use DSM-5 criteria for ADHD, which requires evidence of symptoms causing significant impairment in at least two settings and symptoms present before age 12. Some providers may use standardized rating scales or request input from family members to confirm symptoms.

Treatment Discussion: If diagnosed with ADHD, your provider will discuss treatment options, including both medication and non-medication approaches. They’ll explain different medication choices, how they work, potential side effects, and what to expect.

Why Strattera Might Be Recommended

Your telehealth provider might recommend Strattera if:

• You have concerns about stimulant medications or a personal/family history of substance abuse
• You’ve experienced problematic side effects from stimulants
• You have anxiety that’s worsened by stimulants
• You prefer a medication that doesn’t require monthly prescriptions
• You have medical conditions that make stimulants risky
• You want 24-hour symptom coverage without the ‘wearing off’ effect

Safety and Red Flags: What Disqualifies Someone from Telehealth ADHD Treatment?

Legitimate telehealth providers carefully screen patients to ensure safety. You may not be eligible for ADHD medication via telehealth if you have:

• Active substance abuse issues: Current drug or alcohol misuse is typically an exclusion criterion, especially for stimulant medications
• Uncontrolled cardiovascular conditions: Severe heart disease, uncontrolled high blood pressure, or recent cardiac events may require in-person evaluation
• Acute mental health crises: Severe, untreated mental health conditions like active suicidal ideation, uncontrolled bipolar disorder, or psychosis typically need in-person psychiatric care first
• History of medication misuse: Evidence of ‘doctor shopping,’ early refills, or taking medications in ways not prescribed
• Certain medical contraindications for Strattera: Narrow-angle glaucoma, recent MAOI use (within 14 days), or severe liver disease

If any of these apply to you, a telehealth provider might recommend an in-person specialist evaluation or offer to coordinate with your existing healthcare team before starting treatment.

Prescription Monitoring Programs and Ongoing Care

Although Strattera isn’t a controlled substance and therefore isn’t tracked in state Prescription Drug Monitoring Programs (PDMPs), your telehealth provider will still review your medication history as part of comprehensive care.

What Ongoing Care Looks Like

Regular Follow-Ups: After starting Strattera, expect follow-up appointments within 2–4 weeks to assess how you’re responding. Because non-stimulants take several weeks to reach full effectiveness, your provider will want to monitor your progress and any side effects.

Dosage Adjustments: Your provider may adjust your dose based on your response and tolerability. Strattera typically starts at a lower dose and is gradually increased to the therapeutic range.

Monitoring: Your provider should check blood pressure, heart rate, and ask about any side effects at each visit. For Strattera specifically, monitoring includes watching for mood changes (especially in young adults), liver function concerns, and cardiovascular effects.

Communication: Between scheduled appointments, you should have a way to reach your provider about concerns or side effects. Legitimate telehealth services provide clear communication channels—not just for emergencies, but for questions that arise during treatment.

How Klarity Health Makes ADHD Treatment Accessible

At Klarity Health, we understand that accessing ADHD care shouldn’t be complicated. Our approach prioritizes both convenience and clinical excellence.

Provider Availability: We match you with board-certified doctors or psychiatric nurse practitioners licensed in your state, typically within 24–48 hours. Our providers have experience diagnosing and treating ADHD in adults and can prescribe both stimulant and non-stimulant medications when clinically appropriate.

Transparent Pricing: We believe you should know what care costs upfront. Whether you’re using insurance or paying out-of-pocket, our pricing is clear with no hidden fees. Many patients find that even our cash-pay rates are competitive with traditional in-office visits when you factor in time off work and transportation.

Insurance and Cash Pay Options: We accept many major insurance plans and also offer affordable cash-pay rates. This flexibility means you can choose the payment option that works best for your situation.

Comprehensive Care Approach: We don’t just prescribe medication. Our providers discuss therapy options, lifestyle strategies, and other supports that can help you manage ADHD effectively. We can also coordinate with your therapist or primary care doctor to ensure continuity of care.

Recent Changes in Telehealth ADHD Prescribing Landscape

The telehealth ADHD space has evolved significantly, especially following regulatory scrutiny of some online platforms in 2022–2023.

Increased Oversight

Several large telehealth startups faced investigations from the DEA and DOJ regarding prescribing practices, leading to industry-wide changes. Reputable providers responded by implementing stricter protocols:

• More thorough patient evaluations
• Mandatory follow-up appointments
• Better documentation requirements
• Coordination with patients’ other healthcare providers
• In some cases, periodic drug screens or treatment agreements for controlled substances

This increased oversight actually benefits patients by ensuring that telehealth ADHD treatment maintains high clinical standards and prevents the ‘pill mill’ practices that gave some early platforms a bad reputation.

What This Means for You

When choosing a telehealth provider, look for services that:

• Require a comprehensive video evaluation (not just a questionnaire)
• Use licensed, credentialed providers
• Follow DSM-5 diagnostic criteria
• Discuss both medication and non-medication treatment options
• Schedule regular follow-ups
• Have clear policies about prescribing controlled substances
• Don’t guarantee prescriptions before evaluating you

If a service seems ‘too easy’—offering prescriptions after a 5-minute chat or guaranteeing medication before evaluation—that’s a red flag. Legitimate care requires a thorough assessment.

Practical Tips for Getting Started with Telehealth ADHD Treatment

Before Your Appointment

Gather Information: Collect any previous medical records, prior ADHD evaluations, report cards showing childhood symptoms, or input from family members who can confirm your symptom history.

Prepare Your History: Write down when you first noticed ADHD symptoms, how they affect your daily life, and any previous treatments you’ve tried. Be ready to discuss your complete medical and mental health history.

Choose a Quiet, Private Space: For your video appointment, find a location where you can speak openly without interruptions. Good lighting and a stable internet connection help ensure clear communication.

During Your Evaluation

Be Honest and Thorough: Your provider can only help you if they have complete information. Be upfront about all symptoms, any substance use history, mental health concerns, and other medications you’re taking. This isn’t about judgment—it’s about safety and finding the right treatment.

Ask Questions: Don’t hesitate to ask about different medication options, potential side effects, how long it takes to work, or what to do if you experience problems. Understanding your treatment helps you stay engaged and compliant.

Discuss Your Goals: What do you hope medication will help you accomplish? Better focus at work? Improved organization at home? Clearer communication in relationships? Sharing your goals helps your provider tailor treatment to your needs.

After Your Appointment

Follow Instructions Carefully: Take your medication exactly as prescribed. For Strattera, consistency is key—it needs to be taken daily to build up in your system and reach therapeutic levels.

Track Your Response: Keep notes about how you’re feeling, any side effects, and whether your ADHD symptoms are improving. This information is invaluable at follow-up appointments.

Attend Follow-Ups: Don’t skip your scheduled check-ins. Regular monitoring ensures your treatment is working and allows for adjustments if needed.

Communicate Changes: If you experience concerning side effects, significant life changes, or new medications prescribed by other doctors, inform your ADHD provider promptly.

Common Misconceptions About Telehealth ADHD Prescriptions

‘Online ADHD prescriptions are automatic’

Reality: Legitimate telehealth evaluations are just as comprehensive as in-person visits. Providers must follow the same diagnostic criteria and safety standards. If a service seems to guarantee medication without thorough evaluation, that’s a warning sign, not a benefit.

‘Non-stimulants aren’t effective’

Reality: While stimulants work for many people, non-stimulants like Strattera can be highly effective, especially for certain patients. They offer unique benefits: no abuse potential, all-day coverage, and they can be helpful for people with co-occurring anxiety. The ‘best’ ADHD medication is the one that works for you with manageable side effects.

‘Telehealth doctors can’t prescribe controlled medications’

Reality: Under current federal rules (extended through December 31, 2025), licensed providers can prescribe controlled ADHD medications via telehealth. Thousands of patients successfully receive stimulant prescriptions through legitimate telehealth platforms. For non-stimulants, there’s never been a restriction—providers have always been able to prescribe Strattera via telehealth.

‘Pharmacies won’t fill telehealth prescriptions’

Reality: Most pharmacies routinely fill legitimate telehealth prescriptions. Electronic prescriptions don’t indicate whether your visit was in-person or via video. Using a reputable telehealth service and maintaining a relationship with one pharmacy helps ensure smooth prescription fills.

Looking Ahead: What to Expect in 2026 and Beyond

The telehealth landscape continues to evolve. Here’s what we’re watching:

DEA Regulations: The current temporary extension for controlled substance telehealth prescribing expires December 31, 2025. The DEA is expected to either extend these flexibilities again or finalize new permanent regulations—possibly including a special telemedicine registration system. A fourth extension for 2026 is currently under review.

State Laws: More states are moving toward permanently expanded telehealth access while also implementing safeguards like mandatory PDMP checks. This balanced approach aims to preserve convenience while preventing misuse.

Quality Standards: The industry is coalescing around best practices for telehealth mental health care, including comprehensive evaluations, regular follow-ups, and coordination with other providers.

For non-stimulant medications like Strattera, the future looks stable since they’ve never been subject to the special telehealth restrictions affecting controlled substances. Regardless of how federal rules for stimulants evolve, telehealth access to non-stimulant ADHD treatment should remain widely available.

Taking the Next Step

If you’re struggling with ADHD symptoms and wondering whether telehealth treatment might work for you, here’s what to do:

Assess Your Needs: Are your symptoms interfering with work, relationships, or daily functioning? Have you had these symptoms since childhood? If so, you might benefit from an ADHD evaluation.

Check Your State Requirements: While most states now allow comprehensive telehealth ADHD treatment, it’s worth understanding any specific requirements in your location. Reputable providers like Klarity Health handle state compliance, but being informed helps you know what to expect.

Choose a Reputable Provider: Look for services with licensed providers, thorough evaluation processes, and clear communication about their approach. At Klarity Health, we combine convenient online access with rigorous clinical standards and accept both insurance and cash pay for maximum flexibility.

Prepare for Your Appointment: Gather relevant information about your symptoms and history. Be ready for a comprehensive evaluation—this ensures you get safe, appropriate care.

Commit to the Process: ADHD treatment isn’t just about getting a prescription—it’s about finding the right medication (or combination of treatments), adjusting as needed, and developing strategies to manage your symptoms long-term.

The Bottom Line

Yes, you can absolutely get ADHD non-stimulant medications like Strattera prescribed via telehealth in 2025. Since these medications aren’t controlled substances, they’re not subject to the complex DEA regulations affecting stimulants. A licensed provider can evaluate you via video, confirm your ADHD diagnosis, and prescribe appropriate treatment—all without requiring an in-person visit in most states.

Telehealth has opened new doors for people who’ve struggled to access ADHD care due to provider shortages, scheduling challenges, or other barriers. When done right, telehealth ADHD treatment offers the same quality of care as traditional in-office visits, with added convenience and often faster access to providers.

If you’re ready to explore whether ADHD treatment might help you function better in work, relationships, and daily life, telehealth offers a legitimate, accessible pathway forward. The key is choosing a reputable provider who prioritizes comprehensive evaluation, ongoing monitoring, and your safety alongside convenience.

Ready to take the next step? Klarity Health connects you with experienced providers who can evaluate your symptoms, discuss treatment options, and help you find an approach that works for your unique situation—often with appointments available within 48 hours.

References

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Controlled Substances’ – Federal Register (via FierceHealthcare), November 2024. Confirms DEA policy extension through December 31, 2025.

2. Sheppard Mullin Healthcare Law Blog – National Law Review, August 15, 2025. Comprehensive 50-state survey of telehealth and in-person visit requirements for controlled substance prescribing.

3. Medical News Today – ‘Is Strattera a Controlled Substance?’, January 14, 2025. Medically reviewed article confirming Strattera (atomoxetine) is not a DEA-controlled substance.

4. RxAgent Telehealth Compliance Blog – ‘The Telehealth Compliance Trap: State-by-State Breakdown’, October 2025. Analysis of state-specific telehealth prescribing rules and compliance requirements.

5. Center for Connected Health Policy (CCHP) – State telehealth laws and reimbursement policies database, accessed November-December 2025. Official source for state-by-state telehealth regulations including Florida, Alabama, and other state-specific requirements.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment